HP
HealthInvest Partners Portfolio holdings
AUM
$234M
1-Year Return
10.88%
This Quarter Return
+13.65%
1 Year Return
+10.88%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$128M
AUM Growth
–
Cap. Flow
+$128M
Cap. Flow
% of AUM
100%
Top 10 Holdings %
Top 10 Hldgs %
52.35%
Holding
45
New
45
Increased
–
Reduced
–
Closed
–
Top Buys
| 1 |
UnitedHealth
UNH
|
+$9.69M |
| 2 |
Eli Lilly
LLY
|
+$9.21M |
| 3 |
Gilead Sciences
GILD
|
+$8.02M |
| 4 |
Cencora
COR
|
+$7.99M |
| 5 |
Merck
MRK
|
+$7.16M |
Top Sells
No sells this quarter
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
UnitedHealth
UNH
$319B
| $9.69M | 7.59% |
+18,408
| New | +$9.69M |
|
|
2
Eli Lilly
LLY
$677B
| $9.21M | 7.21% |
+15,805
| New | +$9.21M |
|
|
3
Gilead Sciences
GILD
$142B
| $8.02M | 6.28% |
+98,974
| New | +$8.02M |
|
|
4
Cencora
COR
$58.7B
| $7.99M | 6.26% |
+38,925
| New | +$7.99M |
|
|
5
Merck
MRK
$207B
| $7.16M | 5.6% |
+65,675
| New | +$7.16M |
|
6
Thermo Fisher Scientific
TMO
$181B
| $6.06M | 4.74% |
+11,415
| New | +$6.06M |
|
7
Cardinal Health
CAH
$36.4B
| $4.84M | 3.79% |
+48,000
| New | +$4.84M |
|
8
Harmony Biosciences
HRMY
$1.86B
| $4.68M | 3.67% |
+145,000
| New | +$4.68M |
|
9
Amgen
AMGN
$149B
| $4.61M | 3.61% |
+16,023
| New | +$4.61M |
|
10
Centene
CNC
$16.3B
| $4.6M | 3.6% |
+62,000
| New | +$4.6M |
|
11
Molina Healthcare
MOH
$9.8B
| $4.52M | 3.54% |
+12,500
| New | +$4.52M |
|
12
Bristol-Myers Squibb
BMY
$94B
| $4.52M | 3.53% |
+88,000
| New | +$4.52M |
|
13
Cigna
CI
$80.8B
| $4.49M | 3.52% |
+15,000
| New | +$4.49M |
|
14
Elevance Health
ELV
$70.2B
| $4.48M | 3.51% |
+9,500
| New | +$4.48M |
|
15
Stryker
SYK
$147B
| $3.83M | 3% |
+12,802
| New | +$3.83M |
|
16
Boston Scientific
BSX
$152B
| $3.75M | 2.93% |
+64,806
| New | +$3.75M |
|
17
Vertex Pharmaceuticals
VRTX
$101B
| $3.71M | 2.91% |
+9,130
| New | +$3.71M |
|
18
Regeneron Pharmaceuticals
REGN
$59.4B
| $3.49M | 2.74% |
+3,979
| New | +$3.49M |
|
19
AbbVie
ABBV
$386B
| $3.28M | 2.57% |
+21,196
| New | +$3.28M |
|
20
IQVIA
IQV
$31.8B
| $2.39M | 1.87% |
+10,340
| New | +$2.39M |
|
21
DexCom
DXCM
$29.9B
| $2.24M | 1.75% |
+18,057
| New | +$2.24M |
|
22
Neurocrine Biosciences
NBIX
$14.1B
| $1.66M | 1.3% |
+12,617
| New | +$1.66M |
|
23
Edwards Lifesciences
EW
$45.5B
| $1.59M | 1.24% |
+20,815
| New | +$1.59M |
|
24
Option Care Health
OPCH
$4.62B
| $1.25M | 0.98% |
+37,223
| New | +$1.25M |
|
25
Pfizer
PFE
$136B
| $1.23M | 0.97% |
+42,820
| New | +$1.23M |
|